Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome

Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome

US Patent 8748483 · Granted Jun 10, 2014

Estimated economic value: $8,255,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020
Exendin-4 derivatives as dual GLP1/glucagon agonists2020
Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists2020
Compounds as peptidic GLP1/glucagon/GIP receptor agonists2019
Functionalized Exendin-4 derivatives2019
Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonist2018
Exendin-4 derivatives as selective glucagon receptor agonists2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Substituted indanone compounds as GPR119 modulators for the treatment of diabete2018
Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists2017